SG10201911652TA - Pyrimidinones as factor xia inhibitors - Google Patents

Pyrimidinones as factor xia inhibitors

Info

Publication number
SG10201911652TA
SG10201911652TA SG10201911652TA SG10201911652TA SG10201911652TA SG 10201911652T A SG10201911652T A SG 10201911652TA SG 10201911652T A SG10201911652T A SG 10201911652TA SG 10201911652T A SG10201911652T A SG 10201911652TA SG 10201911652T A SG10201911652T A SG 10201911652TA
Authority
SG
Singapore
Prior art keywords
pyrimidinones
factor xia
xia inhibitors
inhibitors
factor
Prior art date
Application number
SG10201911652TA
Inventor
Andrew K Dilger
James R Corte
Lucca Indawati De
Tianan Fang
Wu Yang
Yufeng Wang
Kumar Balashanmuga Pabbisetty
William R Ewing
Yeheng Zhu
Ruth R Wexler
Donald J P Pinto
Michael J Orwat
Ii Leon M Smith
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG10201911652TA publication Critical patent/SG10201911652TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG10201911652TA 2014-10-01 2015-07-29 Pyrimidinones as factor xia inhibitors SG10201911652TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462058316P 2014-10-01 2014-10-01

Publications (1)

Publication Number Publication Date
SG10201911652TA true SG10201911652TA (en) 2020-02-27

Family

ID=53784023

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201702576QA SG11201702576QA (en) 2014-10-01 2015-07-29 Pyrimidinones as factor xia inhibitors
SG10201911652TA SG10201911652TA (en) 2014-10-01 2015-07-29 Pyrimidinones as factor xia inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201702576QA SG11201702576QA (en) 2014-10-01 2015-07-29 Pyrimidinones as factor xia inhibitors

Country Status (33)

Country Link
EP (4) EP3089979B1 (en)
JP (4) JP6462865B2 (en)
KR (2) KR101921436B1 (en)
CN (3) CN110734435B (en)
AR (1) AR101367A1 (en)
AU (3) AU2015324530B2 (en)
CA (1) CA2963395C (en)
CL (1) CL2017000712A1 (en)
CO (1) CO2017003833A2 (en)
CY (2) CY1119678T1 (en)
DK (2) DK3089979T3 (en)
EA (1) EA031590B1 (en)
ES (3) ES2963267T3 (en)
HR (2) HRP20171950T1 (en)
HU (2) HUE052812T2 (en)
IL (2) IL251434B (en)
LT (2) LT3293186T (en)
MA (1) MA40123A1 (en)
MX (2) MX2017003695A (en)
MY (1) MY183987A (en)
NO (1) NO2721243T3 (en)
PE (2) PE20170939A1 (en)
PH (2) PH12017500580B1 (en)
PL (1) PL3089979T3 (en)
PT (2) PT3089979T (en)
RS (2) RS61183B1 (en)
SG (2) SG11201702576QA (en)
SI (2) SI3089979T1 (en)
TN (2) TN2018000229A1 (en)
TW (3) TWI769442B (en)
UY (1) UY36244A (en)
WO (1) WO2016053455A1 (en)
ZA (1) ZA201702478B (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
NO2760821T3 (en) 2014-01-31 2018-03-10
HUE040226T2 (en) * 2014-01-31 2019-02-28 Bristol Myers Squibb Co Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
WO2016036893A1 (en) 2014-09-04 2016-03-10 Bristol-Myers Squibb Company Diamide macrocycles that are fxia inhibitors
NO2721243T3 (en) * 2014-10-01 2018-10-20
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
CN107001391B (en) 2014-10-01 2020-11-27 默克专利股份公司 Boronic acid derivatives
JOP20160086B1 (en) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
EP3310777B1 (en) 2015-06-19 2019-10-09 Bristol-Myers Squibb Company Diamide macrocycles as factor xia inhibitors
ES2937156T3 (en) 2015-07-29 2023-03-24 Bristol Myers Squibb Co Macrocyclic factor XIa inhibitors bearing a non-aromatic P2' group
ES2803659T3 (en) 2015-07-29 2021-01-28 Bristol Myers Squibb Co Macrocyclic factor xia inhibitors containing p2 alkyl or cycloalkyl moieties
JOP20160198B1 (en) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
JO3633B1 (en) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
EP3423458A1 (en) 2016-03-02 2019-01-09 Bristol-Myers Squibb Company Diamide macrocycles having factor xia inhibiting activity
SG11201808138YA (en) 2016-03-31 2018-10-30 Janssen Pharmaceuticals Inc Substituted indole derivatives as dengue viral replication inhibitors
MA44498A (en) 2016-03-31 2019-02-06 Janssen Pharmaceuticals Inc SUBSTITUTED INDOLINE DERIVATIVES USED AS DENGUE VIRUS REPLICATION INHIBITORS
JOP20170069B1 (en) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc Substituted indoline derivatives as dengue viral replication inhibitors
EA201892200A1 (en) 2016-04-01 2019-03-29 Янссен Фармасьютикалз, Инк. SUBSTITUTED DERIVATIVE COMPOUNDS OF INDOL AS AN INGIBITORS FOR DENG VIRUS REPLICATION INHIBITORS
WO2018133793A1 (en) * 2017-01-18 2018-07-26 广东东阳光药业有限公司 Blood coagulation factor xia inhibitor and uses thereof
JOP20180025B1 (en) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc Substituted indoline derivatives as dengue viral replication inhibitors
JOP20180026A1 (en) 2017-03-31 2019-01-30 Univ Leuven Kath Substituted indoline derivatives as dengue viral replication inhibitors
KR102625991B1 (en) 2017-05-22 2024-01-16 얀센 파마슈티칼즈, 인코포레이티드 Substituted indoline derivatives as dengue virus replication inhibitors
US11407715B2 (en) 2017-05-22 2022-08-09 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
MX2021012286A (en) * 2019-04-11 2022-04-06 Bristol Myers Squibb Co Novel synt.
EA202192753A1 (en) * 2019-04-11 2022-01-11 Бристол-Маерс Сквибб Компани INCREASED EFFICIENCY OF AMORPHOUS SOLID AND SOLUBILIZED COMPOSITIONS TO ACHIEVE THERAPEUTIC PLASMA CONCENTRATIONS
WO2020211781A1 (en) 2019-04-16 2020-10-22 南京明德新药研发有限公司 Macrocyclic derivatives acting as xia factor inhibitor
US20220281868A1 (en) * 2019-07-23 2022-09-08 Medshine Discovery Inc. Macrocyclic derivatives as factor xia inhibitors
JP7450024B2 (en) * 2019-09-27 2024-03-14 シェンヅェン サルブリス ファーマシューティカルズ カンパニー リミテッド FXIa inhibitor and its preparation method and pharmaceutical use
PE20231071A1 (en) * 2020-04-10 2023-07-17 Bristol Myers Squibb Co CRYSTALLINE FORMS OF (9R,13S)-13-{4-[5-CHLORO-2-(4-CHLORO-1H-1,2,3-TRIAZOL-1- IL)PHENYL]-6-OXO-1,6 -DIHYDROPYRIMIDIN-1-IL}-3-(DIFLUOROMETHYL)-9-METHYL-3,4,7,15-TETRAAZATRICYCLO[12.3.1.02,6]OCTADECA-1(18),2(6),4,14, 16-PENTAEN-8-ONE
TW202229280A (en) * 2020-10-12 2022-08-01 美商必治妥美雅史谷比公司 A process toward the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6h)-one
CN115215867B (en) * 2021-04-21 2023-12-26 上海美悦生物科技发展有限公司 FXIa inhibitor, pharmaceutical composition, preparation method and application thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3065190D1 (en) 1979-11-05 1983-11-10 Beecham Group Plc Enzyme derivatives, and their preparation
PE121699A1 (en) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma BICYCLE HETERO CYCLES DISSTITUTED AS INHIBITORS OF THROMBIN
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
WO2000076970A2 (en) 1999-06-14 2000-12-21 Eli Lilly And Company Serine protease inhibitors
DE19962924A1 (en) 1999-12-24 2001-07-05 Bayer Ag Substituted oxazolidinones and their use
AR035216A1 (en) 2000-12-01 2004-05-05 Astrazeneca Ab MANDELIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE DERIVATIVES, USE OF THESE DERIVATIVES FOR THE MANUFACTURE OF MEDICINES, TREATMENT METHODS, PROCESSES FOR THE PREPARATION OF THESE DERIVATIVES, AND INTERMEDIARY COMPOUNDS
CH1427415H1 (en) 2001-09-21 2023-12-21 Bristol Myers Squibb Holdings Ireland LACTAM-CONTAINING COMPOUNDS AND THEIR DERIVATIVES AS FACTOR XA INHIBITORS
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
TWI577665B (en) * 2010-02-11 2017-04-11 必治妥美雅史谷比公司 Macrocycles as factor xia inhibitors
US9327839B2 (en) 2011-08-05 2016-05-03 General Atomics Method and apparatus for inhibiting formation of and/or removing ice from aircraft components
TW201311689A (en) * 2011-08-05 2013-03-16 必治妥美雅史谷比公司 Novel macrocycles as factor XIa inhibitors
TW201319068A (en) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 Cyclic P1 linkers as factor XIa inhibitors
EP3290413B9 (en) * 2011-12-21 2020-04-29 ONO Pharmaceutical Co., Ltd. Pyridinone and pyrimidinone derivatives as factor xia inhibitors
CN108250199B (en) * 2012-08-03 2021-07-16 百时美施贵宝公司 Dihydropyridone P1 as factor XIA inhibitor
UY34959A (en) * 2012-08-03 2014-01-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware DIHYDROPIRIDONE P1 AS INHIBITORS OF THE XIA FACTOR
HUE040226T2 (en) * 2014-01-31 2019-02-28 Bristol Myers Squibb Co Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
NO2760821T3 (en) * 2014-01-31 2018-03-10
NO2721243T3 (en) * 2014-10-01 2018-10-20

Also Published As

Publication number Publication date
MX2020010840A (en) 2020-11-06
EA031590B1 (en) 2019-01-31
NZ766570A (en) 2024-01-26
CA2963395A1 (en) 2016-04-07
TWI692478B (en) 2020-05-01
PE20170939A1 (en) 2017-07-13
EP4286372A3 (en) 2024-02-21
ZA201702478B (en) 2019-06-26
TW201613923A (en) 2016-04-16
EA201790595A1 (en) 2017-07-31
MA40123A1 (en) 2017-09-29
SG11201702576QA (en) 2017-04-27
SI3293186T1 (en) 2021-01-29
CN106795161B (en) 2019-10-15
EP4286372A2 (en) 2023-12-06
BR112017006702A2 (en) 2017-12-26
IL276470A (en) 2020-09-30
HUE038061T2 (en) 2018-09-28
CN110734435B (en) 2022-06-07
KR20180126612A (en) 2018-11-27
AU2021245098A1 (en) 2021-10-28
WO2016053455A1 (en) 2016-04-07
EP3828186A3 (en) 2021-07-28
PE20210922A1 (en) 2021-05-19
JP7317905B2 (en) 2023-07-31
JP2023134734A (en) 2023-09-27
TWI769442B (en) 2022-07-01
CL2017000712A1 (en) 2017-11-03
EP3293186A1 (en) 2018-03-14
IL251434B (en) 2020-08-31
HRP20171950T1 (en) 2018-02-23
TWI834182B (en) 2024-03-01
NO2721243T3 (en) 2018-10-20
TN2018000229A1 (en) 2019-10-04
IL276470B (en) 2021-04-29
JP2021185182A (en) 2021-12-09
CN114957255A (en) 2022-08-30
CA2963395C (en) 2023-03-14
CN106795161A (en) 2017-05-31
NZ731416A (en) 2024-01-26
SI3089979T1 (en) 2017-12-29
LT3293186T (en) 2020-12-28
CY1123663T1 (en) 2022-03-24
JP2017530157A (en) 2017-10-12
AU2015324530B2 (en) 2019-10-24
TW202310844A (en) 2023-03-16
ES2836270T3 (en) 2021-06-24
RS56786B1 (en) 2018-04-30
PH12017500580A1 (en) 2017-08-30
PL3089979T3 (en) 2018-02-28
LT3089979T (en) 2017-12-27
KR102269999B1 (en) 2021-06-25
HRP20201927T1 (en) 2021-02-05
PT3293186T (en) 2020-12-09
AU2015324530A1 (en) 2017-05-18
PH12020500195A1 (en) 2021-02-08
CN110734435A (en) 2020-01-31
CO2017003833A2 (en) 2017-07-11
EP3089979A1 (en) 2016-11-09
EP3293186B1 (en) 2020-09-23
AU2020200376B2 (en) 2021-07-08
AR101367A1 (en) 2016-12-14
TW202043228A (en) 2020-12-01
DK3089979T3 (en) 2018-01-15
UY36244A (en) 2016-01-29
KR101921436B1 (en) 2018-11-22
JP6462865B2 (en) 2019-01-30
KR20170057431A (en) 2017-05-24
AU2021245098B2 (en) 2023-11-23
TN2017000112A1 (en) 2018-07-04
DK3293186T3 (en) 2020-12-14
MY183987A (en) 2021-03-17
ES2963267T3 (en) 2024-03-26
EP3089979B1 (en) 2017-10-18
CY1119678T1 (en) 2018-04-04
EP3828186B1 (en) 2023-08-23
EP3828186A2 (en) 2021-06-02
ES2655884T3 (en) 2018-02-22
MX2017003695A (en) 2017-05-30
PH12017500580B1 (en) 2017-08-30
JP6937734B2 (en) 2021-09-22
JP2019069989A (en) 2019-05-09
PT3089979T (en) 2018-01-16
IL251434A0 (en) 2017-05-29
AU2020200376A1 (en) 2020-02-06
RS61183B1 (en) 2021-01-29
HUE052812T2 (en) 2021-05-28

Similar Documents

Publication Publication Date Title
IL276470B (en) Pyrimidinones as factor xia inhibitors
IL287113A (en) Smyd inhibitors
IL246785A0 (en) Benzimidazol-2-amines as midh1 inhibitors
IL247018A0 (en) Heterocyclic compound
HK1226398A1 (en) Benzimidazol-2-amines as midh1 inhibitors
SG11201610904UA (en) Syk inhibitors
EP3134408A4 (en) FACTOR XIa INHIBITORS
IL248895A0 (en) Phosphatidylinositol -kinase inhibitors
EP3148542A4 (en) Factor xia inhibitors
EP3183255C0 (en) Spiropyrrolidines as mdm2 inhibitors
EP3104701A4 (en) Factor xia inhibitors
EP3180327A4 (en) FACTOR XIa INHIBITORS
EP3180317A4 (en) FACTOR XIa INHIBITORS
IL285105A (en) Heterocyclic compound
IL250022A0 (en) Novel substituted pyrimidine compounds
EP3104702A4 (en) Factor xia inhibitors
EP3104703A4 (en) Factor xia inhibitors
EP3368036A4 (en) Factor xia inhibitors
EP3180325A4 (en) FACTOR XIa INHIBITORS
EP3102571A4 (en) Substituted pyrimidines useful as egfr-t790m kinase inhibitors
AP2016009506A0 (en) Pyrimidine compound
SG11201803357TA (en) Pyrimidine derivative
GB201418154D0 (en) Inhibitors